# Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct06162572/  
OnCo record `nct06162572` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Servier Bio-Innovation LLC, active and no longer recruiting.

## Summary

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 1/2 interventional study registered as NCT06162572 by Servier Bio-Innovation LLC, with 102 participants enrolled, started 2024-08-07 and due to reach its primary completion in 2027-04. Interventions recorded: S095018, S095024, S095029, S095018 Recommended Dose Expansion (RDE), S095024 RDE. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06162572
- Phase: 1/2
- Setting: A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression
- Sponsor: Servier Bio-Innovation LLC
- Enrolled: 102

## Sources

- ClinicalTrials.gov NCT06162572: https://clinicaltrials.gov/study/NCT06162572

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/)
- companies: [Servier](https://onco.cc/companies/servier/)

---
JSON: https://onco.cc/api/v1/entities/nct06162572.json